China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN), securing exclusive rights to promote the German company’s Stivarga (regorafenib) and Nexavar (sorafenib) in mainland China.
Yifan Pharma’s Portfolio
Yifan Pharma has a team of 300 specialists in oncology marketing and sales. Its product lineup includes Xeloda (Capecitabine), Valcyte (valganciclovir), Stivarga, Nexavar, and more.
Market Performance
Stivarga, an oral multi-kinase inhibitor, was first approved in China in March 2017 and covered by the National Reimbursement Drug List (NRDL) in 2018. Despite Bayer’s failure to secure a spot for the originator in last December’s 10th volume-based procurement (VBP) round, Stivarga was involved in the process. Nexavar, a multi-target kinase inhibitor, was first approved in China in September 2006 and included in the NRDL in 2017, though it did not secure a spot during the fourth VBP tender round in February 2021.-Fineline Info & Tech
Leave a Reply